CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 100 target
Drug / intervention
Turmeric extract +1 moredietary
Likely dose
Control: Placebo. 500mg gelatin in capsules 2 times a dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07284316
NCT07284316Phase 3ActiveOn TrackUpdated 3mo ago

Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance: A Randomized Clinical Trial

Instituto Mexicano del Seguro Social·interventional·Posted Dec 16, 2025·Updated Mar 25, 2026

In Brief

A Phase 3 clinical trial evaluating Turmeric extract and Control: Placebo. 500mg gelatin in capsules 2 times a day for Cognitive Decline and 2 related conditions. Active but no longer recruiting, targeting 100 participants across 1 site.

Detailed Summary

Introduction: The Insulin resistance itself has been recognized as an independent risk factor for dementia development. Insulin plays an important role in the regulation of muscle function and the processes of learning and memory. Insulin resistance is associated with increased inflammation and oxidative stress. These processes are involved in the pathophysiology of neurodegenerative diseases. Thus, reducing IR could have implications for improving metabolism, muscle, and cognitive function. Methods and analysis. The investigators will conduct a randomized, double-blind, placebo-controlled clinical trial in which a multidomain program, including an aerobic and cognitive exercise program, will be evaluated. The latter is an exercise program conducted on a checkered mat and will be randomized to participants receiving turmeric plus black pepper or placebo. Participants are affiliated with the Mexican Social Security Institute (IMSS) and are between 55 and 74 years old. The program will last for 24 weeks; after 52 weeks, it will be repeated. The outcomes that the investigators will evaluate are: global cognitive function, specific cognitive function, and the investigators will evaluate serum markers of inflammation, oxidative stress, and GSK-3beta levels. The effect of the interventions on each variable will be analyzed by ANOVA, and a multivariate analysis study with multiple linear regression will be conducted. Ethics and dissemination of the study: the study was approved by the IMSS National Ethics and Research Committee all participants provided written informed consent prior to their participation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
Collaborators--

Timeline

Phase 3Active
20262027
First PostedDec 16, 2025
Enrollment StartFeb 20, 2025
Primary CompletionFeb 15, 2027
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7 months agoPrimary completion in 7 months

Interventions

Turmeric extractdietary

The intervention group includes aerobic exercise and cognitive exercise (grid mat), nutritional guidance, a healthy aging program, turmeric capsules, and black pepper

Control: Placebo. 500mg gelatin in capsules 2 times a dayother

The control group includes an aerobic exercise program and cognitive exercise (grid mat with various patterns of complexity, applied by a health professional), nutritional guidance, and healthy aging program, plus a placebo.